Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 87
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2017  |  Volume : 6  |  Issue : 3  |  Page : 135-144

Tumor necrosis factor-alpha antibodies in fistulizing crohn's disease: An updated systematic review and meta-analysis


1 Department of Pharmacoeconomics and Pharmaceutical Administration, Pharmaceutical Management and Economics Research Centre, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Toxicology and Pharmacology, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
3 Division of Pharmaceutical and Narcotic Affaire, Deputy of Food and Drug, Kurdistan University of Medical Science, Sanandaj, Iran
4 Department of Pharmacoeconomics and Pharmaceutical Administration, Pharmaceutical Sciences Research Centre, Tehran University of Medical Sciences, Tehran, Iran

Correspondence Address:
Shekoufeh Nikfar
Department of Pharmacoeconomics and Pharmaceutical Administration, Pharmaceutical Sciences Research Centre, Tehran University of Medical Sciences, Tehran
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jrpp.JRPP_17_46

Rights and Permissions

Medical treatment for fistulizing Crohn's disease (FCD) is changing rapidly over the time by the introduction of novel therapeutic medicines, while no global consensus is available. This study aims to accomplish a systematic review and meta-analysis on the efficacy of tumor necrosis factor-alpha antibodies (anti-TNF-α antibodies) versus placebo in FCD. A systematic review of published literature was carried out till December 2016, and a meta-analysis of identified studies was done. Data have been explored from PubMed, Scopus, Cochrane Library Database, and Web of Science. Predefined exclusion criteria for included studies in meta-analysis are based on search methodology and are as follows: Randomized clinical trial about Crohn's disease (CD) patients without fistula, pediatrics CD, randomized clinical trials about pregnant women with FCD, nonhuman studies, randomized clinical trials with surgical therapies interventions, conference abstracts, case reports, and language other than English studies. All randomized placebo-controlled trials were included. To assess risk of bias, Jadad score was applied to evaluate trials' methodological quality. Relative risk (RR) and 95% confidence intervals were computed using Mantel-Haenszel and/or Rothman-Boice (for fixed effects) or Der Simonian-Laird (for random effects) techniques. Nine studies attained defined inclusion criteria. The meta-analysis results showed that anti-TNF-α antibodies are remarkably more effective in comparison to placebo for fistula closure maintenance (RR = 2.36; 95% confidence interval: 1.58–3.55; P < 0.0001) in patients with FCD, whereas anti-TNF-α antibodies were not superior to placebo neither in fistula improvement nor in fistula closure. We concluded that adalimumab and certolizumab pegol are both effective in fistula closure maintenance in adult patients with FCD.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed188    
    Printed6    
    Emailed0    
    PDF Downloaded68    
    Comments [Add]    

Recommend this journal